1
Clinical Trials associated with Vax NK/HCC(Vaxcell-Bio Therapeutics)A Phase 2a Study Using Natural Killer (NK) Cell Therapy Combined With Hepatic Artery Infusion Chemotherapy (HAIC) in Patients With Locally Advanced Hepatocellular Carcinoma
This Phase 2a trial will evaluate the safety and efficacy of NK cell therapy combined with the hepatic artery infusion chemotherapy (HAIC) in patients with intermediate and/or locally advanced hepatocellular carcinoma (HCC). We hypothesized that 5-fluorouracil (FU) with immunomodulatory functions would relieve the immunosuppressive microenvironment from the myeloid-derived suppressor cells (MDSCs), thereby enhancing the anti-tumor activity of NK cells. Thus, the subsequent infusion of autologous NK cells (VAX-NK/HCC) following HAIC treatment may further improve the anti-tumor activity in patients with advanced HCC.
100 Clinical Results associated with Vax NK/HCC(Vaxcell-Bio Therapeutics)
100 Translational Medicine associated with Vax NK/HCC(Vaxcell-Bio Therapeutics)
100 Patents (Medical) associated with Vax NK/HCC(Vaxcell-Bio Therapeutics)
100 Deals associated with Vax NK/HCC(Vaxcell-Bio Therapeutics)